

# Hypoparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H44F2CCE54E7EN.html>

Date: September 2022

Pages: 58

Price: US\$ 2,000.00 (Single User License)

ID: H44F2CCE54E7EN

## Abstracts

Hypoparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Drugs In Development, 2022, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the

descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4 and 2 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoparathyroidism - Companies Involved in Therapeutics Development

Aerami Therapeutics Inc

Aeterna Zentaris Inc

Amolyt Pharma

Ascendis Pharma AS

BridgeBio Pharma Inc

Eli Lilly and Co

Entera Bio Ltd

Extend Biosciences Inc

GC Biopharma Corp

MBX Biosciences Inc

ProLynx LLC

Rani Therapeutics LLC

Hypoparathyroidism - Drug Profiles

Aerami-701 - Drug Profile

Product Description

Mechanism Of Action

AEZS-150 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AZP-3601 - Drug Profile

Product Description

Mechanism Of Action

History of Events

encalaret - Drug Profile

Product Description

Mechanism Of Action

History of Events

EXT-608 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

MBX-2109 - Drug Profile

Product Description

Mechanism Of Action

History of Events

palopegteriparatide - Drug Profile

Product Description

Mechanism Of Action

History of Events

PLX-134 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RT-110 - Drug Profile

Product Description

Mechanism Of Action

Stem cell Therapy - Drug Profile

Product Description

Mechanism Of Action

teriparatide - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Discontinued Products

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

Sep 12, 2022: New long-term data in adult patients with hypoparathyroidism treated with Ascendis Pharma's TransCon PTH through Week 110 in the PaTH forward trial

presented at ASBMR 2022

Aug 31, 2022: Ascendis pharma submits TransCon PTH new drug application to the U.S. FDA for adult patients with hypoparathyroidism

Jul 26, 2022: MBX Biosciences receives Orphan Drug Designation for lead candidate MBX 2109 for the treatment of hypoparathyroidism

Jun 14, 2022: Ascendis Pharma announces two oral presentations highlighting the potential for TransCon PTH to be a replacement therapy for adult hypoparathyroidism at ENDO 2022

Jun 14, 2022: BridgeBio Pharma to present phase 2b data and pivotal phase 3 study design of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference

Jun 13, 2022: BridgeBio Pharma shares positive phase 2b data and announces pivotal study design for phase 3 trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1)

May 01, 2022: Ascendis Pharma to present TransCon PTH new endocrinology results at Medical Meetings in May

Mar 13, 2022: Ascendis Pharma announces phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism met primary and all key secondary endpoints

Mar 02, 2022: Aeterna Zentaris announces notice of allowance for U.S. patent covering AEZS-150 for the potential treatment of chronic hypoparathyroidism

Nov 18, 2021: Ascendis Pharma announces top-line results from Week 84 of its phase 2 PaTH forward trial demonstrating that TransCon PTH provided durable benefit and was well-tolerated in adults with hypoparathyroidism

Oct 01, 2021: BridgeBio Pharma announces updated phase 2b data for Encaleret in autosomal dominant hypocalcemia type 1 (ADH1) demonstrating blood and urine calcium normalization in trial participants

Sep 22, 2021: Ascendis Pharma announces mean bone mineral density (BMD) data from phase 2 PaTH Forward Trial demonstrating continued normalization and stabilization of BMD Z-scores between 26 and 58 weeks

Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update

Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type

Appendix

Methodology

Coverage

Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hypoparathyroidism, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2022

Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2022

Hypoparathyroidism - Pipeline by Amolyt Pharma, 2022

Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2022

Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2022

Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2022

Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2022

Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2022

Hypoparathyroidism - Pipeline by GC Biopharma Corp, 2022

Hypoparathyroidism - Pipeline by MBX Biosciences Inc, 2022

Hypoparathyroidism - Pipeline by ProLynx LLC, 2022

Hypoparathyroidism - Pipeline by Rani Therapeutics LLC, 2022

Hypoparathyroidism - Dormant Projects, 2022

Hypoparathyroidism - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hypoparathyroidism, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Hypoparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H44F2CCE54E7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H44F2CCE54E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

